Iulia Diaconu

As we approach the 15th Annual @World ADC meeting in San Diego, we are excited to explore potential partnerships and collaborations in the cutting-edge field of Antibody Drug Conjugates (ADCs) for oncology. ADCs are transforming cancer treatment by precisely targeting cancer cells, administering potent therapies directly where they are needed, while protecting healthy tissue in the process. We are particularly looking forward to Scientific Officer Lynn Kamen’s presentation titled, "Bioanalytical Strategies for Antibody Drug Conjugate Development," scheduled for November 5th from 6:30-7:30 PM. In her talk, Dr. Kamen will delve into vital bioanalytical strategies for assessing ADC pharmacokinetics and immunogenicity, emphasizing the significance of both molecular components for ensuring efficacy and safety. Join us in connecting with researchers and industry leaders as we work towards advancing oncology treatments. We can't wait to see you at booth 518 in San Diego! https://bit.ly/4dTJZVa #WorldADC #ADC #PharmaInnovation #Biotech #DrugDevelopment #BioAgilytix #AntibodyDrugConjugates #InnovationInBiotech

43

Western blot analysis of BrainSim™ protein lysates demonstrates an increase in OPC marker PDGFRa expression over time, with peak expression occurring at DIV70/DIV84. Learn more about BrainSim™ at https://buff.ly/3ItjPeQ #Neuroimaging #Biotech #Biotechnology #FromtheLab #microscopy

18

AP Biosciences, Inc. has posted details for a Phase 1/2, multi-regional, multi-center, open-label, first-in-human, dose-escalation and dose expansion study to evaluate the effects of AP402 in HER2-positive patients with locally or advanced solid tumors. AP402, developed by AP Biosciences and integrated with the T-cube Bispecific Antibody Platform, specifically targets the p95HER2 variant, a common HER2 variant that lacks the extracellular domain, making it untargetable by conventional HER2 therapies. The bivalent binding activity of AP402 to both HER2v and CD137 is superior to monovalent binding of other bispecific antibodies. AP402 can efficiently trigger CD137 activation in T cells through HER2v clustering.  Due to start in December 2024, the study will enroll an estimated 85 patients. #mabs https://lnkd.in/efDY2EW9

7

Thanks for the coverage, The Antibody Society. APBio's latest T-cell engager, AP402, targets #p95HER2, a truncated form of the notorious #HER2 receptor. Unlike the full-length HER2, p95HER2 lacks almost entire N-terminal extracellular domain, including the trastuzumab binding site, but retains its C-terminal domain. This truncated isoform is present in approximately 30–40% of patients with metastatic, therapy-resistant HER2-positive #BreastCancer. Notably, p95HER2 remains highly active in downstream signaling pathways, a factor associated with poor prognosis in patients expressing high levels of this isoform. Targeting p95HER2 with therapies like AP402 may offers a promising alternative for patients whose HER2-positive breast cancers have relapsed or are refractory to trastuzumab and its related therapies.

12

Christian Ramirez Amarilla now at #BITS2024 about how inhibiting METTL3, an important RNA methyltransferase, affects RNA structure, adenosine-to-inosine (A-to-I) editing, and the immune response in leukemia models, providing new insights into potential therapeutic approaches for leukemia. #Bioinformatics #LeukemiaResearch #BITS2024

53

#CARTcelltherapy offers needed treatment options for rare diseases. In light of recent #FDA approvals (https://lnkd.in/ee8pv7BN), learn how Judi by AG Mednet supported a prominent clinical-stage #biotech on a pivotal Phase 2 CAR-T #oncology trial using our Judi for Eligibility and Judi for Adjudication solutions.

9

Check out this article! Our experts Krishnendu Khan, Ph.D. and Rui Li share their insights to better understand how to select cryo containers that meet the specific needs of your cryopreservation application and safeguard the #celltherapy! #Biotechnology #Biologics

13

Our CSO Graeme Smith recently presented our latest advancements in targeting DNA Polymerase Theta (Polθ) at the Dana Farber Center for BRCA & Related Genes Annual Scientific Symposium. The symposium fostered invaluable exchanges on cutting-edge research and emerging clinical data. Polθ is a critical enzyme predominantly active in cancer cells, supporting a DNA repair mechanism essential for tumor survival. Our lead clinical candidate, ART6043, is specifically designed to inhibit Polθ and disrupt this cancer-dependent repair pathway while sparing healthy cells. By targeting this unique vulnerability, ART6043 has demonstrated potential in preclinical models to enhance the efficacy of other therapies like PARP inhibitors and offer promising strategies for tackling aggressive or treatment-resistant cancers. Learn more about our progress here: https://lnkd.in/eep6PUhH. #OncologyInnovation #PolTheta #CancerResearch #DrugDevelopment 

127

1 Comment

This article by Peter Tessier and colleagues in BioDrugs provides an overview of conventional and emergent single B cell screening approaches and highlights their potential strengths and weaknesses. #BCells #antibodydiscovery #infectiousdisease https://lnkd.in/gwfaf6Ch

20

🔬 A crucial discussion unfolded at #AAPSPharmSci360, as industry leaders tackled the FDA's transformative laboratory-developed test (LDT) proposed rule and its implications for biomarker testing at last month's conference in Salt Lake City.   The high-impact session, moderated by our Chief Scientific Officer, Dr. Lauren Stevenson, brought together expert perspectives from Stephen Piccoli (Sun Pharma), Patrice Hugo (IQVIA Laboratories), and Mark Ma (Rallybio).   The session revealed critical insights into the FDA's April 2024 LDT Final Rule, fundamentally reshaping how diagnostic and exploratory biomarker tests are regulated. Under this new framework, LDTs will transition from their current enforcement discretion policy to being regulated as medical devices.   The implications are significant: industry data suggests 200-400 clinical studies could face delays over the next three years, potentially affecting 30,000-45,000 patients. We're proud to see Immunologix Laboratories contributing to these vital industry discussions.   Read the full article by Bioanalysis Zone here: https://lnkd.in/eTvyRRgY   As a specialized bioanalytical CRO, we understand firsthand how these evolving regulations will reshape pharmaceutical development. Our expertise in this space allows us to offer strategic guidance to sponsors through:   💠 Sophisticated biomarker strategies coupled with depth of regulatory expertise 💠 Custom biomarker assay development and validation 💠 Method transfer and optimization for context of use 💠 PK/PD analysis This regulatory evolution presents both challenges and opportunities for our industry. As we look ahead, our scientific team remains committed to delivering innovative, compliant solutions that advance drug development programs and ultimately benefit patients.   Thank you to AAPS for facilitating these critical conversations that help shape the future of our industry!   #Bioanalysis #DrugDevelopment #Biomarkers #CRO #PharmaceuticalScience #RegulatoryScience #ImmunologixLabs

10

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

51

The abstract submission deadline for the Cell Symposia: Chemical biology in drugging the undrugged is approaching fast, July 26. This symposium will bring together researchers from diverse disciplines to discuss the current state of and future opportunities in the chemical-biology-medicine continuum, with a goal of advancing drug discovery and development. Submit your abstract by July 26 and join the program. https://hubs.li/Q02DS9ZC0

2

The Chemist's Playbook: Impactful Bioisosteres for Modern Drug Design | https://lnkd.in/gJ-RmHbW Thu, Oct 24, 2024  8 AM PDT / 11 AM EDT / 5 PM CEST The ever-expanding drug discovery enterprise began to exploit bioisosterism as a form of molecular recognition to identify and advance candidate molecules. There are many reasons to explore biosiosteres in drug discovery. May it be to improve potency or drug-like properties or to eliminate an undesired potential toxicophore. In this Flash Talk, Nicholas A. Meanwell will explore the history of bioisosterism. He will present several case studies with established and emerging bioisosteres addressing a range of challenges in drug discovery. He will dive into examples of carboxylic acid, amide, phosphate, phenyl and hydrogen bioisosteres focusing on molecule case studies that had an impact on the contemporary pharmacopeia. Don't miss this Flash Talk by a renowned expert in the field. Following the presentation, Nicholas will be available to answer your questions during a live Q&A session. Register here: https://lnkd.in/gJ-RmHbW

374

4 Comments

New hope in #Cancer treatment! Scripps Research team identifies potential targets for future cancer drugs using an innovative protein-mapping approach. Findings may enable researchers to create more precise therapies to stop cell multiplication. Quick Read: https://lnkd.in/gA_kxkdQ #Bioinformatics #CancerResearch #DrugDiscovery #ScienceNews #biotechnology

16

🌟 New Article Alert: Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors🌟 Fab Biopharma is pioneering bispecific soluble receptor therapies to address complex autoimmune diseases like Sjögren’s and lupus. These innovative molecules engage both T and B cells while avoiding the cross-linking risks of traditional bispecific antibodies, offering a more precise, targeted approach. In our newest article authored by Fab Biopharma Co-Founders Reiner Gentz, Ph.D and Gardiner Smith, J.D, discover how our receptors are designed to modulate, not suppress, immune responses — a critical advancement for diseases where immune function must be carefully balanced. Read the full article here: https://lnkd.in/eG8BgmbN #DrugDevelopment #WomensHealth #BiopharmaInnovation #LifeSciences

3

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2